SEC Form 4 · accession 0001479290-18-000019
Revance Therapeutics, Inc. · RVNC
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Abhay Joshi
Officer — Chief Operating Officer
Period of report
Feb 8, 2018
Accepted (ET)
Feb 9, 2018 · 9:13 pm EST
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001479290
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Feb 8, 2018 | A | 11,750 | $0.00 | A | 85,106 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Employee Stock Option (Right to Buy)F2 | $29.15 | Feb 8, 2018 | A | 70,500 | A | — | Feb 7, 2028 | Common Stock | 70,500 | 70,500 | D |
Explanation of responses
- F1The shares subject to the Restricted Stock Award shall vest in three (3) equal annual installments beginning from March 15, 2018, subject to Dr. Joshi's Continuous Service (as defined in the Issuer's 2014 Equity Incentive Plan (the "Plan")) on each vesting date.
- F2The shares subject to the stock option shall vest in forty-eight (48) equal monthly installments beginning from February 8, 2018, subject to Dr. Joshi's Continuous Service (as defined in the Plan) on each vesting date.